Search Within

Sergio Andres Giralt

  1. "Elsevier Inc."
Formats
  1. Meeting Abstract (252)
  2. Journal Article (129)
  3. Guidelines (2)
  4. Research Letter (2)
  5. Review (1)
Groups
  1. Bone Marrow Transplant (386)
  2. Center for Hematologic Malignancies (386)
  3. Department of Medicine (386)
  4. Hematologic Malignancies, Division of (386)
  5. Survivorship Research (270)
  6. CTCR Scholars (221)

More Groups

People
  1. Miguel-Angel Perales (171)
  2. Sean Devlin (145)
  3. Gunjan Shah (122)
  4. Molly Maloy (113)
  5. Ann Jakubowski (112)
  6. Esperanza Papadopoulos (103)

More People

Years
  1. 2025 (3)
  2. 2024 (17)
  3. 2023 (22)
  4. 2022 (26)
  5. 2021 (13)
  6. 2020 (38)

More Years

Publications
  1. Biology of Blood and Marrow Transplantation (275)
  2. Clinical Lymphoma, Myeloma and Leukemia (60)
  3. Transplantation and Cellular Therapy (36)
  4. Journal of Geriatric Oncology (3)
  5. International Journal of Radiation Oncology, Biology, Physics (2)
  6. Journal of Pain and Symptom Management (2)

More Publications

Publishers
  1. Elsevier Inc. (386)

Results (386)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Aging-related, senescence-associated secretory phenotype and allogeneic hematopoietic cell transplantation outcomes in older patients
    Research Letter

    Jeng, M. Y.; Wong, P.; Flynn, J. R.; Ritter, E.; Ho, C.; Ruiz, J. D.; Jakubowski, A. A.; Papadopoulos, E. B.; Shaffer, B. C.; Ponce, D. R.; more...
    Journal of Geriatric Oncology (2025)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma: A real-world experience
    Journal Article

    Hultcrantz, M.; Derkach, A.; Hassoun, H.; Korde, N.; MacLachlan, K.; Mailankody, S.; Patel, D.; Shah, U. A.; Tan, C. R.; Chung, D. J.; more...
    Blood Neoplasia (2025)

    Fulltext@MSK | Save
  • Shift from widespread to tailored antifungal prophylaxis in lymphoma patients treated with CD19 CAR T cell therapy: Results from a large retrospective cohort
    Journal Article

    Melica, G.; Luna de Abia, A.; Shah, G. L.; Devlin, S.; Corona, M.; Fein, J.; Dahi, P. B.; Giralt, S. A.; Lin, R. J.; Palomba, M. L.; more...
    Transplantation and Cellular Therapy (2025)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens (SRs) in triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): KarMMa-3 sub-analysis of black patients
    Meeting Abstract

    Patel, K. K.; Rodríguez-Otero, P.; Nooka, A. K.; Callander, N. S.; Solomon, S. R.; Baz, R.; Sborov, D. W.; Gergis, U.; Badros, A. Z.; Giralt, S. A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with Talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Comprehensive genomic sequencing predicts sub-optimal response to bispecific antibodies (BsAb) and chimeric antigen receptor T cells (CAR-T) in multiple myeloma (MM)
    Meeting Abstract

    Maclachlan, K.; Shekarkhand, T.; Farzana, T.; Costa, B.; Firestone, R.; Jurgens, E.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Shah, U.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Clinical outcomes of teclistamab among MajesTEC-1 eligible and ineligible population in the real-world setting for the treatment of relapsed/refractory multiple myeloma
    Meeting Abstract

    Tan, C.; Derkach, A.; Maclachlan, K.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Rajeeve, S.; Hashmi, H.; Shah, G.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Impact of granulocyte colony-stimulating factor exposure on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma
    Meeting Abstract

    Wang, A.; Shekarkhand, T.; Derkach, A.; Nemirovsky, D.; Tan, C.; Hamadeh, I.; Firestone, R.; Jurgens, E.; Miller, K.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Incidence and clinical impact of acute kidney injury: A comparison of CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B.; Farzana, T.; Jurgens, E.; Firestone, R.; Nath, K.; Chung, D.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save
  • Phase I trial of MCARH109, a first-in-class G Protein Coupled Receptor Class C Group 5 Member D (GPRC5D)-targeted CAR T-cell therapy for relapsed or refractory multiple myeloma: Updated analysis
    Meeting Abstract

    Jurgens, E.; Firestone, R.; Chaudhari, J.; Hosszu, K.; Devlin, S.; Shah, U.; Landa, J.; McAvoy, D.; Lesokhin, A.; Korde, N.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2024)

    Fulltext@MSK | Save